US 11,806,338 B2
Non-aqueous liquid nimodipine compositions
Hugh Greg Thomas, Carrollton, GA (US)
Assigned to AZURITY PHARMACEUTICALS, INC., Woburn, MA (US)
Filed by Azurity Pharmaceuticals, Inc., Woburn, MA (US)
Filed on Nov. 19, 2021, as Appl. No. 17/530,728.
Application 17/530,728 is a continuation of application No. 16/722,513, filed on Dec. 20, 2019, granted, now 11,207,306.
Application 16/722,513 is a continuation of application No. 16/407,980, filed on May 9, 2019, granted, now 10,576,070, issued on Mar. 3, 2020.
Application 16/407,980 is a continuation of application No. 15/954,357, filed on Apr. 16, 2018, granted, now 10,342,787, issued on Jul. 9, 2019.
Claims priority of provisional application 62/621,953, filed on Jan. 25, 2018.
Prior Publication US 2022/0071974 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4422 (2006.01); A61K 47/10 (2017.01); A61K 9/08 (2006.01); A61P 25/00 (2006.01)
CPC A61K 31/4422 (2013.01) [A61K 9/08 (2013.01); A61K 47/10 (2013.01); A61P 25/00 (2018.01)] 16 Claims
 
1. A syringe containing a non-aqueous liquid composition comprising:
nimodipine as the only active ingredient wherein the concentration of nimodipine is about 6 mg/mL; and
one or more solvents selected from ethanol, isopropanol, butanol, isobutanol, glycerin, and polyethylene glycol;
wherein the non-aqueous liquid composition comprises less than 1% water by volume;
wherein about 5% or less nimodipine degradation is observed over a period of at least three months when exposed to 40° C. and 75% relative humidity.